UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000050454
Receipt number R000057459
Scientific Title Radio-frequency-ablation for lung cancer under general anesthesia
Date of disclosure of the study information 2023/04/01
Last modified on 2023/02/28 18:10:11

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Radio-frequency-ablation for lung cancer under general anesthesia

Acronym

Radio-frequency-ablation for lung cancer under general anesthesia

Scientific Title

Radio-frequency-ablation for lung cancer under general anesthesia

Scientific Title:Acronym

Radio-frequency-ablation for lung cancer

Region

Japan


Condition

Condition

Primary lung cancer and metastatic lung cancer

Classification by specialty

Chest surgery Radiology

Classification by malignancy

Malignancy

Genomic information

NO


Objectives

Narrative objectives1

While radio-frequency-ablation (RFA) for lung cancer has been conducted under local anesthesia, it has the following disadvanteges:
(1) Tumor position is usually changed under due to respiration, RFA-prove sometimes falls off the tumor.
(2) During the treatment, temperature of the probe increases, which inflicts pains for patients like burn.
(3) During the treatment, bronchial bleeding sometimes causes airway obstruction.
To eliminate these shortcomings, general anesthesia using tracheal intubation is conducted for RFA for lung cancer.

Basic objectives2

Safety,Efficacy

Basic objectives -Others


Trial characteristics_1

Exploratory

Trial characteristics_2

Pragmatic

Developmental phase

Phase II


Assessment

Primary outcomes

safety and efficacy

Key secondary outcomes

5 years recurrence-free survival


Base

Study type

Interventional


Study design

Basic design

Single arm

Randomization

Non-randomized

Randomization unit


Blinding

Open -no one is blinded

Control

Uncontrolled

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

1

Purpose of intervention

Treatment

Type of intervention

Maneuver

Interventions/Control_1

For patients with primary or metastatic lung cancer less than 3 cm, the followings are explained: 1. Standard treatment is surgery if resectable, 2. As non-surgical treatment, radiation therapy is the first choice, 3. As another non-surgical treatment, the radio-frequency ablation is also available. When the patient requests the radio-frequency ablation, it will be done.

Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

10 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

1. Stage I primary lung cancer less than 3 cm.
2. Metastatic lung cancer less than 3 cm.
3. Patient requests RFA.

Key exclusion criteria

Sever pulmonary dysfunction

Target sample size

500


Research contact person

Name of lead principal investigator

1st name Hiroaki
Middle name
Last name Nomori

Organization

Kashiwa Kousei General Hospital

Division name

Department of thoracic surgery

Zip code

277-8551

Address

Shikoda 617, Kashiwa-city, Chiba prefecture

TEL

0471451111

Email

hnomori@qk9.so-net.ne.jp


Public contact

Name of contact person

1st name Hiroaki
Middle name
Last name Nomori

Organization

Kashiwa Kousei General Hospital

Division name

Department of thoracic surgery

Zip code

277-8551

Address

Shikoda 617, Kashiwa city, Chiba prefecture

TEL

0471451111

Homepage URL


Email

hnomori@qk9.so-net.ne.jp


Sponsor or person

Institute

Kashiwa Kousei General Hospital

Institute

Department

Personal name



Funding Source

Organization

None

Organization

Division

Category of Funding Organization

Self funding

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

Kashiwa Kousei General Hospital

Address

Shikoda 617, Kashiwa city, Chiba prefecture

Tel

0471451111

Email

hnomori@qk9.so-net.ne.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2023 Year 04 Month 01 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Preinitiation

Date of protocol fixation

2023 Year 02 Month 28 Day

Date of IRB


Anticipated trial start date

2023 Year 04 Month 01 Day

Last follow-up date

2033 Year 03 Month 31 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2023 Year 02 Month 28 Day

Last modified on

2023 Year 02 Month 28 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000057459


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name